Intensity Therapeutics
Latest round
- Series A
Last raised
- Jun 2016
Total raised
- $10M
Investors
- 3
About Intensity Therapeutics
Based in the US, Intensity Therapeutics, Inc.Founded in 2012 and headquartered in Norwalk, US, Intensity Therapeutics, Inc. specializes in developing therapies for solid tumors.5 million in an IPO.Intensity Therapeutics specializes in innovative cancer treatment solutions through its proprietary intratumoral delivery technology. The company's core offering, INT230-6, leverages its DfuseRx? penetration enhancer platform to enable therapeutic agents to be injected directly into solid tumors, resulting in improved absorption and enhanced diffusion of drugs into cancer cells. This localized treatment approach aims to facilitate cancer cell death while simultaneously activating a systemic immune response, thereby allowing immune cells to effectively target and attack tumors throughout the body. The primary end users include patients with metastatic cancer, especially those undergoing presurgical interventions, as well as healthcare providers in oncology and clinical research settings.The revenue model for Intensity Therapeutics revolves around the sale of its flagship product, INT230-6, and potentially future products developed through its proprietary technology platform. Transactions are structured through partnerships with healthcare institutions, clinical trial collaborations, and possibly direct sales to oncology practices, where the drug would be administered to patients. The company may also engage in collaborations with pharmaceutical companies or research organizations for further development and commercialization of its drug candidates. Given the nature of these products, pricing strategies could be aligned with value-based pricing models that reflect the therapeutic benefits provided to patients.In July 2023, Intensity Therapeutics, Inc.9 million shares at USD 5 per share on the NASDAQ. Intensity Therapeutics is exploring new markets in regions beyond North America and Europe, although specific details and timelines for these expansions have not been disclosed.
Who invested in Intensity Therapeutics
3 investors across 1 round
See all investors in Intensity Therapeutics
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Funding rounds
Series A
Jun 28, 2016
Amount
$10M
Investors
Questions about Intensity Therapeutics
Who invested in Intensity Therapeutics?
Intensity Therapeutics has 3 investors on record across 1 venture round. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Intensity Therapeutics raised?
Intensity Therapeutics has raised 1 venture round. Sign up free to see how much each round raised and the total.
When did Intensity Therapeutics last raise money?
Intensity Therapeutics's most recent round on record is a Series A, in Jun 2016.
What does Intensity Therapeutics do?
Based in the US, Intensity Therapeutics, Inc.
Where is Intensity Therapeutics headquartered?
Intensity Therapeutics is headquartered in Norwalk, US.
Which VCs invest in companies like Intensity Therapeutics?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back biotechnology companies at Intensity Therapeutics's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series A
Raising like Intensity Therapeutics? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.